Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Details : CT-95 is a MSLN x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN neoplasms.
Product Name : CT-95
Product Type : Antibody
Upfront Cash : Inapplicable
April 09, 2025
Integral’s Out-Licensed Bispecific Antibody Enters Solid Tumor Trial
Details : CTIM-76 is an anti-Claudin 6 (CLDN6) bispecific antibody, which is currently being evaluated for the treatment of platinum-refractory/resistant ovarian cancer.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
March 06, 2025
Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76
Details : CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. It is being evaluated for the treatment of Claudin 6-Positive gynecologic and testicular cancers.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Nextech
Deal Size : $100.0 million
Deal Type : Private Placement
Context Therapeutics Announces $100 Million Private Placement
Details : The net proceeds will be used to fund the clinical development of CTIM-76, under early-stage trials for CLDN6-positive ovarian, lung, and testicular tumors.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Undisclosed
February 05, 2024
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Nextech
Deal Size : $100.0 million
Deal Type : Private Placement
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Context Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of CTIM-76
Details : CTIM-76 is a Claudin 6 x CD3 T cell engaging bispecific antibody, which is currently being evaluated for the treatment of patients with CLDN6-positive gynecologic and testicular cancers.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Context Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Details : CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. It is being evaluated for the treatment of Claudin 6-Positive gynecologic and testicular cancers.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
January 04, 2024
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format. It is is potent with specific lysis of CLDN6+ cancer cells over normal cells.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Lonza Inc & Lonza America Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells ...
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Lonza Inc & Lonza America Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Integral Molecular
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers.
Product Name : CTIM-76
Product Type : Antibody
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : CTIM-76
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Integral Molecular
Deal Size : Inapplicable
Deal Type : Inapplicable